Collectively, our findings identify IGFBP2 as a pivotal regulator within the HCC EMT axis, whereby its overexpression confers the distinctly aggressive clinical features characteristic of the disease. The gene discussed is IGFBP2; the disease is hepatocellular carcinoma.